Genomic Strategies for Understanding the Pathophysiology of Autism Spectrum Disorder

Miyuki Doi1,2, Mengwei Li1, Noriyoshi Usui1,2,3,4* and Shoichi Shimada1,2,3,4

1 Department of Neuroscience and Cell Biology, Graduate School of Medicine, Osaka University, Suita, Japan, 2 Addiction Research Unit, Osaka Psychiatric Research Center, Osaka Psychiatric Medical Center, Osaka, Japan, 3 United Graduate School of Child Development, Osaka University, Suita, Japan, 4 Global Center for Medical Engineering and Informatics, Osaka University, Suita, Japan

Recent breakthroughs in sequencing technology and technological developments have made it easier to analyze the entire human genome than ever before. In addition to disease-specific genetic mutations and chromosomal aberrations, epigenetic alterations in individuals can also be analyzed using genomics. Autism spectrum disorder (ASD) is a neurodevelopmental disorder (NDD) caused by genetic and/or environmental factors. More than a thousand genes associated with ASD have been identified which are known to be involved in brain development. However, it is difficult to decode the roles of ASD-associated genes without in vitro and in vivo validations, particularly in the process of brain development. In this review, we discuss genomic strategies for understanding the pathological mechanisms underlying ASD. For this purpose, we discuss ASD-associated genes and their functions, as well as analytical strategies and their strengths and weaknesses in cellular and animal models from a basic research perspective.

Keywords: genomics, autism spectrum disorder (ASD), gene, mutation, cellular model, animal model, morphology, behavior

INTRODUCTION

ASD is an NDD caused by genetic and/or environmental factors, as reported in many epidemiological studies. ASD symptoms are heterogeneous and are characterized by social communication deficits, repetitive behaviors, and hyperesthesia/hypesthesia (Lord et al., 2018, 2020). The number of ASD patients is increasing worldwide. In the latest report, the prevalence of ASD was reported to be 1 in 44 (2.27%) in the US (Maenner et al., 2021; Shaw et al., 2021). Nevertheless, no effective treatment has been developed to date. Although early intervention for ASD has been reported to improve symptoms (White et al., 2007; Dawson et al., 2012; Rogers et al., 2012), this depends on symptomatic treatment such as cognitive behavioral therapy. Therefore, it is necessary to develop early treatment and diagnostic methods as soon as possible. To understand the pathophysiology underlying ASD, identification of causative genes in individuals and environmental factors during fetal development, and research and development using cellular and animal models, have been undertaken.

Genetic and/or environmental factors contribute to the pathogenesis of ASD (Lord et al., 2018, 2020; Doi et al., 2022). Massive genome-wide association studies (GWASs) in ASD have been conducted using advanced next-generation sequencing (NGS) technology. Over a thousand ASD-associated genes have been identified in individuals with ASD, suggesting that ASD is a
highly complex disorder (Iossifov et al., 2014; Toma et al., 2014; Griswold et al., 2015; Wilkinson et al., 2015; Yao et al., 2015; Satterstrom et al., 2020; Wang et al., 2020). Most ASD genes are known to play roles in fetal brain development, particularly in neurogenesis, neuronal migration, neural differentiation, and synaptogenesis (Tebbenkamp et al., 2014; Wang et al., 2014; de la Torre-Ubieta et al., 2016; Doi et al., 2022). Furthermore, environmental factors, such as maternal immune activation (MIA), stress, undernutrition, and drug exposure have also been investigated to understand the pathophysiology of ASD (Beversdorf et al., 2005; Christensen et al., 2013; Gumusoglu and Stevens, 2019; Meyer, 2019; Courchesne et al., 2020; Doi et al., 2022).

To investigate the involvement and functions of these ASD genes, there are several strategies that use cellular and animal models instead of humans. For cellular models, morphological and electrophysiological phenotypes in cells can be evaluated by manipulating the expression of ASD genes using cell culture systems (Gordon and Geschwind, 2020). In recent years, studies using organoids cultured in three dimensions, in addition to neural cells and intermediate progenitor cells, have been conducted (Kelley and Pašca, 2022). As for animal models, various animal species such as mice, rats, macaques, zebrafish, fruit flies and nematodes are widely used, often taking advantage of powerful genome editing technology. The strength of animal models is their ability to analyze gene function at the individual gene level. In particular, neural circuit and behavioral analyses are the most important features of animal models (Silverman et al., 2010; Kazdoba et al., 2016a).

Here, we review the genomic strategies for understanding the pathophysiology of ASD. In this review, we first discuss how ASD genes have been identified and the brain functions to which they have been traced. We will also review strategies for understanding the pathophysiology of ASD, focusing on cellular and animal models and their advantages and disadvantages, and introduce the latest research findings and strategies, including our own.

EXPLORATION AND IDENTIFICATION OF ASD-ASSOCIATED GENES

Among the genetic studies, twin studies have contributed to the identification of factors involved in the pathogenesis of ASD. Since the first twin study on ASD in 1977, which reported a higher concordance in monozygotic (MZ) twins than in dizygotic (DZ) twins for ASD (Folstein and Rutter, 1977), many studies have applied twin designs (Ronald and Hoekstra, 2011; Sandin et al., 2014). Furthermore, a meta-analysis of twin studies conducted in 2015 estimated a heritability of 64–91% (Tick et al., 2016). Based on these studies, it is widely accepted that genetic factors play a crucial role in ASD pathogenesis. Some genetic disorders consistently linked to ASD, including Angelman syndrome, fragile X syndrome, tuberous sclerosis, Rett syndrome, and other MECP2-related disorders, Smith-Lemli-Opitz syndrome, phenylketonuria, Cohen syndrome, Smith-Magenis syndrome, Sanfilippo syndrome, adenosylcinnamate lyase deficiency, Down syndrome, 22q13 deletion syndrome (Cohen et al., 2005; Bukelis et al., 2007).

Progress in genetics over the past few decades has provided insights into the genomic and molecular mechanisms underlying ASD. Earlier studies using microarray and next-generation sequencing, such as whole exome sequencing (WES) and whole genome sequencing (WGS), have identified contributions from both rare (e.g., de novo and inherited mutations) and common variants [e.g., copy number variants (CNVs) and single nucleotide variants (SNVs); State and Levitt, 2011; de la Torre-Ubieta et al., 2016; Muhle et al., 2018]. Unlike inherited mutations, which are passed from the parent, de novo mutations are spontaneous "novel" mutations that arise in gametes or fertilized eggs, and cannot be identified in the parent. CNVs are chromosomal abnormalities which include deletions, duplications, or amplifications in chromosomal structure; it has been found that there are multiple chromosomal abnormalities associated with ASD recurring at specific loci (Sanders et al., 2011). Sanders et al. also reported two or more recurrent deletions and duplications at multiple loci, such as deletions at 16p11.2 and duplications at 15q13.2–13.3 in patients with ASD (Sanders et al., 2011).

Although common variants are estimated to have a more substantial impact than rare variants on ASD liability (Klei et al., 2012; Lee et al., 2013; Gaugler et al., 2014), many genome-wide association studies (GWAS) have been insufficient to identify even a single SNV with genome-wide significance until recently, owing to the massive number of variants involved as well as the low risk associated with ASD individually (Wang et al., 2009; Anney et al., 2010, 2012; Autism Spectrum Disorders Working Group of The Psychiatric Genomics Consortium, 2017). In other words, investigating the influence of single SNVs requires a large sample number. However, a study published in 2019, employing a huge cohort and strict analysis, identified 34 high-confidence ASD (hcASD) risk genes at multiple genetic loci (Grove et al., 2019). They also reported that these ASD-candidate genes are more highly expressed during the embryonic stage than during the postnatal stages, suggesting their roles in fetal brain development (Courchesne et al., 2019).

Considering the significance of heritability and intricate genetic factors in ASD, a thorough database of known ASD-associated genes would be invaluable. SFARI gene (https://gene.sfari.org/) is a well-known database of ASD-associated genes (Banerjee-Basu and Packer, 2010) which is widely used in ASD research. In SFARI, each gene is categorized into one of four groups: S (syndromic), 1 (high confidence), 2 (strong candidate), and 3 (suggestive evidence). In addition, SFARI gene provides functional information on ASD genes, making it an indispensable tool for investigating the effect of a gene during development. For example, one of the frequently reported ASD genes, SHANK3, is a multidomain scaffold protein involved in the regulation of the structural organization of dendritic spines (Durand et al., 2007). Another frequently reported ASD-associated gene, MECP2, plays a crucial role in chromatin modification and RNA silencing (Li and Pozzo-Miller, 2020). CNTNAP2 modulates cell adhesion, dendritic arborization, and spinogenesis (Li and Pozzo-Miller, 2020). FOXPI is also frequently reported to be involved in
The utility of cellular models in ASD studies is that human cells such as patient-derived induced pluripotent stem cells (iPSCs) can be used to avoid ethical issues (Bellin et al., 2012). It is also more feasible to study a relatively simple system rather than a complicated one in the living body. In addition, cellular models often require less time and space than animal models. It is expected that the development of ASD modeling at the cellular level will promote at least a partial understanding of the functional and morphological characteristics underlying ASD pathophysiology (Gordon and Geschwind, 2020). Furthermore, cellular models that reflect pathological conditions can be helpful tools for drug development; therefore, versatile cellular models are attracting increasing attention.

There are multiple options for the selection of cellular models. The first method is to use cells derived directly from individuals with ASD. Patient-derived iPSCs are a powerful tool for understanding ASD pathophysiology. A method for introducing mutations identified in patients with ASD into iPSCs is also used. Another option is to use genetic recombination or gene-editing techniques to uncover the function of ASD-associated genes using primary cultured neural cells or cell lines. For example, Marchetto et al. (2017) reprogrammed fibroblasts to generate iPSCs, neural progenitor cells (NPCs), and neurons from ASD individuals, and found that abnormal neurogenesis and synaptogenesis resulted in functional defects in neural networks in ASD. Deneault et al. selected ASD-associated genes based on their WES results and generated knockout (KO) iPSCs using CRISPR/Cas9 genome editing. They classified cells based on their transcriptome data and found that similar electrophysiological phenotypes can be produced by ASD-associated genes from different classifications (Deneault et al., 2018). Hashimoto et al. (2016) identified ASD-associated genes with de novo SNVs using trio-based WES in the ASD family, and generated knockdown neuroblastoma cells to investigate their morphological characteristics.

It is well-known that both neurons and glia (astrocytes, oligodendrocytes, and microglia) contribute to the pathophysiology of ASD. Knockdown of the ASD-associated gene NRXN1 using shRNA in NPCs resulted in inhibition of astrogenesis. Furthermore, astrocytes generated from iPSC derived from ASD individuals with NRXN1 deletions show abnormal morphology and proliferation (Lam et al., 2019). In another study, Allen et al. (2022) transplanted astrocytes generated from ASD individual-derived organoids into the mouse brain and observed repetitive behavior, cognitive deficits, and abnormal neuronal activity in the transplanted mice. In addition, aberrant myelination has been reported in ASD postmortem brain (Fetit et al., 2021). Such myelin is formed by oligodendrocytes. In the study of ASD-associated gene ZBTB16, the reduced numbers of oligodendrocytes as well as impairment of cortical myelination have been reported in Zbtb16 KO mice, which displayed ASD-like behaviors (Usui et al., 2021).

![Gene ontology of ASD genes](https://www.sfari.org/resource/sfari-gene)

**CELLULAR MODELS FOR UNDERSTANDING ASD PATHOPHYSIOLOGY**

The expanding knowledge of ASD genes and their functions offers further insights into ASD pathogenesis. Efforts have been made in epigenomics for many identified ASD-associated genes involved in epigenetic pathways, such as MECP2. A significant reduction in MECP2 in the frontal cortex of individuals with ASD has been reported, suggesting that disruption of DNA methylation plays a role in ASD pathogenesis (Nagarajan et al., 2006). Other epigenomic studies have found similar aberrations in histone acetylation (Sun et al., 2016), correlating with DNA methylation variations in the prefrontal and temporal cortices (Wong et al., 2019). In addition to postmortem brain samples and blood samples have also been used in ASD-associated DNA methylation examination (Andrews et al., 2018), suggesting a potentially more convenient approach for DNA methylation studies of ASD. It seems that epigenomics might be ideal for finding patterns of convergence among heterogeneous ASD-associated genes and addressing the complex effects resulting from the interaction of genomics and the environment.

Together, studies on the genetic contributions to ASD pathogenesis are crucial to elucidate ASD etiology and fetal brain development. These genomic studies also provide insights into the heterogeneity of ASD, which is thought to contribute to the complexity of ASD pathogenesis.
Increased numbers of synapses have been reported in ASD postmortem brain (Tang et al., 2014; de la Torre-Ubieta et al., 2016). Since microglia play a role in synaptic pruning, microglial dysfunction can disrupt the synaptic excitatory and inhibitory balance (E/I balance). E/I imbalance is one of the explanations for the pathophysiology of ASD (Koyama and Ikegaya, 2015). Moreover, an increasing number of activated microglia and abnormal morphological changes have been reported in the frontal lobes and cerebellum of ASD individuals (Andoh et al., 2019).

As described above, human cells can be used in cellular models, and offer an advantage that animal models do not. In recent years, it has become possible to construct tissues by three-dimensional culture, such as organoids; research is being conducted to mimic the development of the human brain and analyze the pathophysiological conditions of the mimicked environment.

**ANIMAL MODELS FOR UNDERSTANDING ASD PATHOPHYSIOLOGY**

In contrast to cellular models, animal models allow one to evaluate individuality, such as behavioral and developmental characteristics. Meanwhile, animal ethics issues, breeding environments, and controls are required, which are space-consuming and costly. It also takes a longer time to generate a model to be used in experiments than cellular models. There are various methods (e.g., KO, knock-in, point mutation, and overexpression) to generate ASD animal models in various species. As a typical example, animal models of ASD are generated by modifying the expression of ASD-associated genes or introducing mutations identified in patients with ASD. Various animal species, such as mice, rats, macaques, zebrafish, fruit flies and nematodes have been used as ASD animal models (Stewart et al., 2014; Escamilla et al., 2017; Zhou et al., 2019; Li et al., 2021; Watanabe et al., 2021; Silverman et al., 2022).

Therefore, researchers can select animal models based on their purpose. For example, it has reported Shank2 KO rats as an ASD model animal and repetitive behaviors as well as hyper activity (Arroyo-Araujo et al., 2019). Zhou et al. (2019) introduced a mutation in the macaque SHANK3 gene. The SHANK3 mutant macaques showed a reduction of its protein level and ASD-like behaviors such as social impairment and repetitive behaviors. The SHANK3 mutant model has been generated in zebrafish. In shank3a knockout zebrafish displayed a decrease of head size and impairment of touch-induced startle response (Stewart et al., 2014).

To assess behavioral phenotypes using animal models, ASD-like behaviors can be evaluated in terms of social and restricted/repetitive behaviors. Social behaviors can be assessed by the three-chamber social interaction, free moving social interaction, social preference, ultrasonic vocalization tests (Silverman et al., 2010; Lammert and Lukens, 2019). Restricted/repetitive behaviors can also be assessed by stereotyped behaviors, such as grooming, rearing, climbing behaviors, and marble burying test (Silverman et al., 2010; Langen et al., 2011; Lammert and Lukens, 2019). For example, a mutation in the transcription factor ZBTB16 was identified in brothers with ASD (Bacchelli et al., 2019). Recently, we reported impairments in social behaviors and increased repetitive behaviors in Zbtb16 KO mice (Usui et al., 2021). Furthermore, histological abnormalities in cortical layer thickness, axon initial segment (AIS) length of neurons, and myelination in the cortex have been reported in Zbtb16 KO mice (Usui et al., 2021, 2022b).

Animal models are also useful for analyzing environmental factors. Previous genomic studies demonstrate that about 20–30% of patients with ASD have abnormal genes (Kazdoba et al., 2016b), suggesting the importance of environmental factors in the onset of ASD. MIA and drug exposure animal models have also been used (Doi et al., 2022; Usui et al., 2022a).

Thus, animal models have advantages over cellular models. In recent years, studies have been conducted from the perspective of systems neuroscience using two-photon microscopy, multi-electrode arrays, and optogenetics, etc., in addition to genomics. Previous studies using these methods have begun to unravel the neural circuits and mechanisms responsible for social behavior, which is one of the main symptoms of ASD.

**FIGURE 2 | Genomic approaches to understand the mechanisms underlying ASD pathophysiology.** To identify the genes involved in the pathophysiology of ASD, genome or gene expression analyses with samples such as blood and postmortem brains from individuals with ASD are performed to identify disease-specific mutations, chromosomal aberrations, and fragile genes. Cellular and animal models are used to analyze the genes identified in ASD individuals, and functional analyses are conducted based on the strength of each model.
DISCUSSION

Analyses of the functions of ASD-associated genes have revealed that most of these genes are involved in fetal brain development. In recent years, provocative studies have been conducted to examine whether ASD can be treated by genome editing during the fetal period, when the brain is dynamically developed. However, given the fact that approximately half of ASD cases can be attributed to genetic factors (Sandin et al., 2014), environmental factors also appear to contribute to the pathogenesis of ASD. Environmental factors such as MIA and drug exposure are known to affect fetal brain development in the prenatal environment (Doi et al., 2022). However, some environmental factors, such as MIA due to infectious diseases, could be more difficult to prevent than genetic factors.

ASD is a heterogeneous neurodevelopmental disorder, and such complexity is largely due to the complexity of the onset factors and is difficult to explain using a simple model. ASD is far more complicated than a single-gene disorder, and has a pathogenesis that is due to the accumulation of many predisposing genes, even if only genetic factors are considered. Furthermore, as suggested by the male-female ratio of ASD prevalence, sex differences further add complexity to the symptoms and pathogenesis of ASD. Future studies on the pathological mechanisms underlying ASD that consider both genetic and environmental factors are required.

In conclusion, genomics is a powerful strategy to understand the pathological mechanisms underlying ASD (Figure 2). The use of animal models is indispensable for understanding complex pathological conditions, but incorporating human findings and pathological conditions will also be essential.

AUTHOR CONTRIBUTIONS

MD: writing—original draft, writing—review and editing, and visualization. ML: writing—original draft and visualization. NU: conceptualization, writing—original draft, writing—review and editing, project administration, and funding acquisition. SS: writing—review and editing, supervision, and funding acquisition. All authors have contributed to the manuscript and approved the submitted version.

FUNDING

This work was supported by the Japan Science and Technology Agency (JST) Center of Innovation Program (COI Program) (JPMJCE1310) to NU and SS; Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research (C) (20K06872) to NU; JSPS Grant-in-Aid for Challenging Research (20K21654) to NU and SS; Uehara Memorial Foundation to NU; Takeda Science Foundation to NU; SENSHIN Medical Research Foundation to NU; Osaka Medical Research Foundation for Intractable Diseases to NU.

REFERENCES

Allen, M., Huang, B. S., Notaras, M. J., Lodhi, A., Barrio-Alonso, E., Lituma, P. J., et al. (2022). Astrocytes derived from ASD individuals alter behavior and destabilize neuronal activity through aberrant Ca(2+) signaling. Mol. Psychiatry 27, 2470–2484. doi: 10.1038/s41380-022-01486-x
Andoh, M., Ikegaya, Y., and Koyama, R. (2019). Microglia as possible therapeutic targets for autism spectrum disorders. Prog. Mol. Biol. Transl. Sci. 167, 223–245. doi: 10.1016/bs.pmbts.2019.06.012
Andrews, S. V., Sheppard, B., Windham, G. C., Schieve, L. A., Schendel, D. E., Croen, L. A., et al. (2018). Case-control meta-analysis of blood DNA methylation and autism spectrum disorder. Mol. Autism 9:40. doi: 10.1186/s13229-018-0224-6
Anney, R., Klei, L., Pinto, D., Almeida, J., Bacchelli, E., Baird, G., et al. (2012). Individual common variants exert weak effects on the risk for autism spectrum disorders. Hum. Mol. Genet. 21, 4781–4792. doi: 10.1093/hmg/ddq301
Anney, R., Klei, L., Pinto, D., Regan, R., Conroy, J., Magalhaes, T. R., et al. (2010). A genome-wide scan for common alleles affecting risk for autism. Hum. Mol. Genet. 19, 4072–4082. doi: 10.1093/hmg/ddq307
Araujo, D. J., Anderson, A. G., Berto, S., Runnels, W., Harper, M., Ammannuel, S., et al. (2015). FoxP1 orchestration of ASD-relevant signaling pathways in the striatum. Genes Dev. 29, 2081–2096. doi: 10.1101/gad.267989.115
Araujo, D. J., Toriumi, K., Escamilla, C. O., Kulkarni, A., Anderson, A. G., Harper, M., et al. (2017). Foxp1 in forebrain pyramidal neurons controls gene expression required for spatial learning and synaptic plasticity. J. Neurosci. 37, 10997–109931. doi: 10.1523/jneurosci.1005-17.2017
Arroyo-Araujo, M., Graf, R., Maco, M., van Dam, E., Schenker, E., Drinkenburg, W. J., et al. (2019). Reproducibility via coordinated standardization: a multicenter study in a Shank2 genetic rat model for Autism Spectrum Disorders. Sci. Rep. 9:16602. doi: 10.1038/s41598-019-47981-0
Bellin, M., Marchetto, M. C., Gage, F. H., and Mummery, C. L. (2012). Induced pluripotent stem cells: the new patient? Nat. Rev. Mol. Cell Biol. 13, 713–726. doi: 10.1038/nrm3448
Beversdorf, D. Q., Manning, S. E., Hillier, A., Anderson, S. L., Nordgren, R. E., Walters, S. E., et al. (2005). Timing of prenatal stressors and autism. J. Autism Dev. Disord. 35, 471–478. doi: 10.1007/s10803-005-0537-8
Bukelis, I., Porter, F. D., Zimmerman, A. W., and Tierney, E. (2007). Smith-Lemli-Opitz syndrome and autism spectrum disorder. Am. J. Psychiatry 164, 1655–1661. doi: 10.1176/ajp.2007.07020315
Christensen, J., Grenborg, T. K., Serensen, M. J., Schendel, D., Parner, E. T., Pedersen, L. H., et al. (2013). Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 309, 1696–1703. doi: 10.1001/jama.2013.2270
Co, M., Hickey, S. L., Kulkarni, A., Harper, M., and Konopka, G. (2020). Cortical Foxp2 supports behavioral flexibility and developmental dopamine D1 receptor expression. Cereb. Cortex 30, 1855–1870. doi: 10.1093/cercor/hbz209
Cohen, D., Pichard, N., Tordjman, S., Baumann, C., Burglen, L., Excoffier, E., et al. (2005). Specific genetic disorders and autism: clinical contribution
towards their identification. *J. Autism Dev. Disord.* 35, 103–116. doi: 10.1007/s10803-004-1038-2

Courchesne, E., Gazestani, V. H., and Lewis, N. E. (2020). Prenatal origins of ASD: the when, what, and how of ASD development. *Trends Neurosci.* 43, 326–342. doi: 10.1016/j.tins.2020.03.005

Courchesne, E., Pramparo, T., Gazestani, V. H., Lombardo, M. V., Pierce, K., and Lewis, N. E. (2019). The ASD Living Biology: from cell proliferation to clinical phenotype. *Mol. Psychiatry* 24, 88–107. doi: 10.1038/s41380-018-0056-y

Dawson, G., Jones, E. J., Merkle, K., Venema, K., Lowy, R., Faja, S., et al. (2012). Early behavioral intervention is associated with normalized brain activity in young children with autism. *J. Am. Acad. Child Adolesc. Psychiatry* 51, 1150–1159. doi: 10.1016/j.jaac.2012.08.018

de la Torre-Ubieta, L., Won, H., Stein, J. L., and Geschwind, D. H. (2016). Advancing the understanding of autism disease mechanisms through genetics. *Nat. Med.* 22, 345–361. doi: 10.1038/nm.4071

Deneault, E., White, S. H., Rodrigues, D. C., Ross, P. J., Faheem, M., Zaslavsky, K., et al. (2014). Most genetic risk for autism resides with common variation. *Nat. Genet.* 46, 881–885. doi: 10.1038/ng.3039

Hashimoto, R., Nakazawa, T., Tsurusaki, Y., Yasuda, Y., Nagayasu, K., Gumusoglu, S. B., and Stevens, H. E. (2019). Maternal inflammation and autism spectrum disorders-associated genes in a case control cohort reveals scaffolding protein SHANK3 are associated with autism spectrum disorders. *Hum. Mol. Genet.* 28, 345–355. doi: 10.1093/hmg/doi.2019.10.003

Doi, M., Usui, N., and Shimada, S. (2022). Prenatal environment and neurodevelopmental disorders. *Front. Endocrinol.* 13, 860110. doi: 10.3389/fendo.2022.860110

Durand, C. M., Betancur, C., Boeckers, T. M., Bokmann, J., Chaste, P., Fauchereau, F., et al. (2007). Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. *Nat. Genet.* 39, 25–27. doi: 10.1038/ng1933

Eisenmuller, C., Germano, S. J., Bodea, C. A., Goldberg, A. P., Lee, A. B., et al. (2014). Most genetic risk for autism resides with common variation. *Nat. Genet.* 46, 881–885. doi: 10.1038/ng.3039

Arenado, G., and Geschwind, D. H. (2016). Human in vitro neuropathology of autism: A systematic review of post-mortem studies. *Neuropathol. Appl. Neurobiol.* 42, 793–806. doi: 10.1111/j.1365-2990.2016.01384.x

Li, Z., Zhu, Y. X., Gou, L. Z., and Cheng, Y. (2021). Understanding autism spectrum disorders with animal models: applications, insights, and perspectives. *Zool. Res.* 42, 800–824. doi: 10.24272/j.issn.2095-8137.2021.251

Li, L., Brigha, T. S., Charron, T., Cusack, J., Dumas, G., Frazier, T., et al. (2020). Autism spectrum disorder. *Nat. Rev. Dis. Primers* 6:5. doi: 10.1038/s41572-019-01318-0

Li, Z., Brigha, T. S., Charron, T., Cusack, J., Dumas, G., Frazier, T., et al. (2020). Autism spectrum disorder. *Nat. Rev. Dis. Primers* 6:5. doi: 10.1038/s41572-019-01318-0

Lammert, C. R., and Lukens, J. R. (2019). Modeling autism-related disorders in mice with maternal immune activation (MIA). *Methods Mol. Biol.* 1960, 227–236. doi: 10.1007/978-1-4939-9167-9_20

Langen, M., Kas, M. J., Staal, W. G., van Engeland, H., and Durston, S. (2011). The neurobiology of repetitive behavior: of mice. *Neurosci. Biobehav. Rev.* 35, 345–355. doi: 10.1016/j.neubiorev.2010.02.004

Lee, S. H., Ripke, S., Neale, B. M., Faraone, S. V., Purcell, S. M., Perlis, R. H., et al. (2013). Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. *Nat. Genet.* 45, 984–994. doi: 10.1038/ng.2711

Lamb, M., Moslem, M., Byriss, J., Pronk, R. L., Uhlin, E., Ellström, I. D., et al. (2019). Single cell analysis of autism patient with bi-allelic NRXN1-alpha deletion reveals skewed fate choice in neural progenitors and impaired neuronal functionality. *Exp. Cell Res.* 383:111469. doi: 10.1016/j.yexcr.2019.06.014

Varoqueaux, F., et al. (2008). Reduced social interaction and ultrasonic communication in mice with maternal immune activation (MIA). *Proc. Natl. Acad. Sci. U.S.A.* 105, 103–108. doi: 10.1073/pnas.0711555105

Varoqueaux, F., et al. (2008). Reduced social interaction and ultrasonic communication in mice with maternal immune activation (MIA). *Proc. Natl. Acad. Sci. U.S.A.* 105, 103–108. doi: 10.1073/pnas.0711555105

Muller, R. A., Reed, H. E., Stratigos, K. A., and Veenstra-VanderWeele, J. (2018). The emerging clinical neuroscience of autism spectrum disorder: a review. *JAMA Psychiatry* 75, 514–523. doi: 10.1001/jamapsychiatry.2017.4685

Nagaijara, R. P., Hogart, A. R., Gwoy, Y., Martin, M. R., and LaSalle, J. M. (2006). Reduced MeCP2 expression is frequent in autism frontal cortex and correlates with aberrant MEC2 promoter methylation. *Epigenetics* 1, e1–11. doi: 10.4161/epi.1.4.3514

Meyer, U. (2019). Neurodevelopmental resilience and susceptibility to maternal immune activation. *Trends Neurosci.* 42, 793–806. doi: 10.1016/j.tins.2018.10.001

Muhle, R. A., Reed, H. E., Stratigos, K. A., and Veenstra-VanderWeele, J. (2018). The emerging clinical neuroscience of autism spectrum disorder: a review. *JAMA Psychiatry* 75, 514–523. doi: 10.1001/jamapsychiatry.2017.4685

Nagaijara, R. P., Hogart, A. R., Gwoy, Y., Martin, M. R., and LaSalle, J. M. (2006). Reduced MeCP2 expression is frequent in autism frontal cortex and correlates with aberrant MEC2 promoter methylation. *Epigenetics* 1, e1–11. doi: 10.4161/epi.1.4.3514

Peçâ, J., Feliciano, C., Ting, J. T., Wang, W., Wells, M. F., Venkatraman, T. N., et al. (2011). Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. *Nature 472, 437–442. doi: 10.1038/nature09965

Rogers, S. J., Estes, A., Lord, C., Vismara, L., Winter, J., Fitzpatrick, A., et al. (2012). Effects of a brief Early Start Denver model (ESDM)-based parent intervention on toddlers at risk for autism spectrum disorders: a randomized controlled trial. *J. Am. Acad. Child Adolesc. Psychiatry* 51, 1052–1065. doi: 10.1016/j.jaac.2012.08.003
Ronald, A., and Hoekstra, R. A. (2011). Autism spectrum disorders and autistic traits: a decade of new twin studies. Am. J. Med. Genet. B Neuropsychiatr. Genet. 156B, 255–274. doi: 10.1002/ajmg.b.31159

Sanders, S. J., Ercan-Sencicek, A. G., Hsu, V., Luo, R., Murtha, M. T., Moreno-Duca, D., et al. (2011). Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. Neurogenet. 70, 68–85. doi: 10.1161/neurogenetics.111.005502

Sandin, S., Lichtenstein, P., Kuja-Halkola, R., Larsson, H., Hultman, C. M., and Reichenberg, A. (2014). The familial risk of autism. JAMA 311, 1770–1777. doi: 10.1001/jama.2014.4144

Satterstrom, F. K., Kosmicik, J. A., Wang, J., Breen, M. S., De Rubeis, S., An, J. Y., et al. (2020). Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism. Cell 180, 568–584.e523. doi: 10.1016/j.cell.2019.12.036

Shaw, K. A., Menninger, M. J., Bakian, A. V., Bild, D. A., Durkin, M. S., Furnier, S. M., et al. (2021). Early identification of autism spectrum disorder among children aged 4 years - autism and developmental disabilities monitoring network, 11 Sites, United States, 2018. MMWR Surveill. Summ. 70, 1–14. doi: 10.15585/mmwr.ss7001a

Silverman, J. L., Thurman, A., Ethridge, S. B., Soller, M. M., Petkova, S. P., Abel, T., et al. (2022). Reconsidering animal models used to study autism spectrum disorder: current state and optimizing future. Genes Brain Behav. 2022:e12803. doi: 10.1111/gbb.12803

Silverman, J. L., Yang, M., Lord, C., and Crawley, J. N. (2010). Behavioural phenotyping assays for mouse models of autism. Nat. Rev. Neurosci. 11, 490–502. doi: 10.1038/nrn2851

State, M. W., and Levitt, P. (2011). The conundrums of understanding genetic risks for autism spectrum disorders. Nat. Neurosci. 14, 1499–1506. doi: 10.1038/nn.2924

Stewart, A. M., Nguyen, M., Wong, K., Poudel, M. K., and Kalueff, A. V. (2014). Developing zebrasfish models of autism spectrum disorder (ASD). Prog. Neuro-Psychopharmacol. Biol. Psychiay 50, 27–36. doi: 10.1016/j.pnpbp.2013.11.014

Sun, W., Poschmann, J., Cruz-Herrera Del Rosario, R., Parikshak, N. N., Hajan, H. S., Kumar, V., et al. (2016). Histone acetylome-wide association study of autism spectrum disorder. Cell 167, 1385–1397.e1311. doi: 10.1016/j.cell.2016.10.031

Tang, G., Gudsnuk, K., Kuo, S. H., Cotrina, M. L., Rosoklija, G., Sosunov, A., et al. (2014). Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits. Neurogenet. 83, 1131–1143. doi: 10.1038/neurogenetics.2014.07.040

Tebbenkamp, A. T., Willsey, A. J., State, M. W., and Sestan, N. (2014). The developmental transcriptome of the human brain: implications for neurodevelopmental disorders. Curr. Opin. Neurol. 27, 149–156. doi: 10.1097/wco.0000000000000669

Tick, B., Bolton, P., Happé, F., Rutter, M., and Rijsdijk, F. (2016). Heritability of autism spectrum disorders: a meta-analysis of twin studies. J. Child Psychol. Psychiay 57, 585–595. doi: 10.1111/jcpp.12499

Toma, C., Torrico, B., Hervás, A., Valdés-Mas, R., Tristán-Noguero, A., Padillo, V., et al. (2014). Exome sequencing in multiplex autism families suggests a major role for heterozygous truncating mutations. Mol. Psychiatry 19, 784–790. doi: 10.1038/mp.2013.106

Usui, N., Araujo, D. J., Kulkarni, A., Co, M., Ellepoge, J., Harper, M., et al. (2017a). Foxp1 regulation of neonatal vocalizations via cortical development. Genes Dev. 31, 2039–2055. doi: 10.1101/gad.305037.117

Usui, N., Berto, S., Konishi, A., Kondo, M., Konopka, G., Matsuzaki, H., et al. (2021). Zbb6 regulates social cognitive behaviors and neocortical development. Transl. Psychiatry 11:242. doi: 10.1038/s41398-021-01358-y

Usui, N., Co, M., Harper, M., Rieger, M. A., Dougherty, J. D., and Konopka, G. (2017b). Sumoylation of FOXP2 regulates motor function and vocal communication through purkinje cell development. Biol. Psychiatry 81, 220–230. doi: 10.1016/j.biopsych.2016.02.008

Usui, N., Co, M., and Konopka, G. (2014). Decoding the molecular evolution of human cognition using comparative genomics. Brain Behav. Evol. 84, 103-116. doi: 10.1159/000365182

Usui, N., Matsumoto-Miyai, K., Koyama, Y., Kobayashi, Y., Nakamura, Y., Kobayashi, H., et al. (2022a). Social communication of maternal immune activation-affected offspring is improved by si-based hydrogen-producing agent. Front. Psychiatry 13:872302. doi: 10.3389/fpsyt.2022.872302

Usui, N., Tian, X., Harigai, W., Togawa, S., Utsunomiya, R., Doi, T., et al. (2022b). Length impairments of the axon initial segment in rodent models of attention-deficit hyperactivity disorder and autism spectrum disorder. Neurochem. Int. 153:105273. doi: 10.1016/j.neuint.2021.105273

Wang, K., Zhang, H., Ma, D., Bucan, M., Glessner, J. T., Abrahams, B. S., et al. (2009). Common genetic variants on 5p14.1 associate with autism spectrum disorders. Nature 459, 528–533. doi: 10.1038/nature07999

Wang, S. S., Kloth, A. D., and Badura, A. (2014). The cerebellum, sensitive periods, and autism. Neuron 83, 518–532. doi: 10.1016/j.neuron.2014.07.016

Wang, T., Hoekzema, K., Vecchio, D., Wu, H., Sulevazi, A., Cho, B. P., et al. (2020). Large-scale targeted sequencing identifies risk genes for neurodevelopmental disorders. Nat. Commun. 11:4932. doi: 10.1038/s41467-020-18723-y

Watanabe, S., Kurotani, T., Oga, T., Noguchi, J., Isoda, R., Nakagami, A., et al. (2021). Functional and molecular characterization of a non-human primate model of autism spectrum disorder shows similarity with the human disease. Nat. Commun. 12:5388. doi: 10.1038/s41467-021-25487-6

White, S. W., Scalifi, L., Klin, A., Koenig, K., and Volkmar, F. R. (2007). Educational placements and service use patterns of individuals with autism spectrum disorders. J. Autism Dev. Disord. 37, 1403–1412. doi: 10.1007/s10803-006-0281-0

Wilkinson, B., Grepo, N., Thompson, B. L., Kim, J., Wang, K., Evgrafov, O. V., et al. (2015). The autism-associated gene chromodomain helicase DNA-binding protein 8 (CHD8) regulates noncoding RNAs and autism-related genes. Transl. Psychiatry 5:e568. doi: 10.1038/tp.2015.62

Wong, C. Y. S., Smith, R. G., Hannon, E., Ramaswami, G., Parikshak, N. N., Assary, E., et al. (2019). Genome-wide DNA methylation profiling identifies convergent molecular signatures associated with idiopathic and syndromic autism in post-mortem human brain tissue. Hum. Mol. Genet. 28, 2201–2211. doi: 10.1093/hmg/ddz052

Yao, P., Lin, P., Gokoolparsadh, A., Assareh, A., Thang, M. W., and Vouineagu, I. (2015). Coexpression networks identify brain region-specific enhancer RNAs in the human brain. Nat. Neurosci. 18, 1168–1174. doi: 10.1038/nn.4063

Zhou, Y., Sharma, J., Ke, Q., Landman, R., Yuan, J., Chen, H., et al. (2019). Atypical behaviour and connectivity in SHANK3-mutant macaques. Nature 570, 326–331. doi: 10.1038/s41586-019-1278-0